Abstract
Variants in the PROM1 gene are associated with cone (−rod) dystrophy, macular dystrophy, and other phenotypes. We describe the clinical and genetic characteristics of 10 patients from eight Japanese families with PROM1-associated retinal disorder (PROM1-RD) in a nationwide cohort. A literature review of PROM1-RD in the Japanese population was also performed. The median age at onset/examination of 10 patients was 31.0 (range, 10–45)/44.5 (22–73) years. All 10 patients showed atrophic macular changes. Seven patients (70.0%) had spared fovea to various degrees, approximately half of whom had maintained visual acuity. Generalized cone (−rod) dysfunction was demonstrated in all nine subjects with available electrophysiological data. Three PROM1 variants were identified in this study: one recurrent disease-causing variant (p.Arg373Cys), one novel putative disease-causing variant (p.Cys112Arg), and one novel variant of uncertain significance (VUS; p.Gly53Asp). Characteristic features of macular atrophy with generalized cone-dominated retinal dysfunction were shared among all 10 subjects with PROM1-RD, and the presence of foveal sparing was crucial in maintaining visual acuity. Together with the three previously reported variants [p.R373C, c.1551+1G'A (pathogenic), p.Asn580His (likely benign)] in the literature of Japanese patients, one prevalent missense variant (p.Arg373Cys, 6/9 families, 66.7%) detected in multiple studies was determined in the Japanese population, which was also frequently detected in the European population.
Original language | English |
---|---|
Pages (from-to) | 656-674 |
Number of pages | 19 |
Journal | American Journal of Medical Genetics, Part C: Seminars in Medical Genetics |
Volume | 184 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2020 Sept 1 |
Keywords
- PROM1
- autosomal dominant
- cone dystrophy
- cone rod dystrophy
- macular dystrophy
ASJC Scopus subject areas
- Genetics
- Genetics(clinical)
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Clinical and genetic characteristics of 10 Japanese patients with PROM1-associated retinal disorder: A report of the phenotype spectrum and a literature review in the Japanese population'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, Vol. 184, No. 3, 01.09.2020, p. 656-674.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Clinical and genetic characteristics of 10 Japanese patients with PROM1-associated retinal disorder
T2 - A report of the phenotype spectrum and a literature review in the Japanese population
AU - Fujinami, Kaoru
AU - Oishi, Akio
AU - Yang, Lizhu
AU - Arno, Gavin
AU - Pontikos, Nikolas
AU - Yoshitake, Kazutoshi
AU - Fujinami-Yokokawa, Yu
AU - Liu, Xiao
AU - Hayashi, Takaaki
AU - Katagiri, Satoshi
AU - Mizobuchi, Kei
AU - Mizota, Atsushi
AU - Shinoda, Kei
AU - Nakamura, Natsuko
AU - Kurihara, Toshihide
AU - Tsubota, Kazuo
AU - Miyake, Yozo
AU - Iwata, Takeshi
AU - Tsujikawa, Akitaka
AU - Tsunoda, Kazushige
N1 - Funding Information: Kaoru Fujinami is supported by grants from Grant-in-Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16H06269), grants from Grant-in-Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16KK01930002), grants from National Hospital Organization Network Research Fund (H30-NHO-Sensory Organs-03), grants from FOUNDATION FIGHTING BLINDNESS ALAN LATIES CAREER DEVELOPMENT PROGRAM (CF-CL-0416-0696-UCL), grants from Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare (201711107A), and grants from Great Britain Sasakawa Foundation Butterfield Awards. Akio Oishi is supported by grants from, Japan Society for the Promotion of Science, Tokyo, Japan (17H06820 and 19K09929). Yu Fujinami-Yokokawa is supported by grants from Grant-in-Aid for Young Scientists of the Ministry of Education, Culture, Sports, Science and Technology, Japan (18K16943). Gavin Arno is supported by a Fight for Sight (UK) Early career investigator award, NIHR-BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, NIHR-BRC at Great Ormond Street Hospital and UCL Institute of Child Health, and Great Britain Sasakawa Foundation Butterfield Award, UK. Nikolas Pontikos is funded by a Moorfields Eye Charity Career Development Award (R190031A), the NIHR-BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology. Toshihide Kurihara is supported by Tsubota Laboratory, Inc, Fuji Xerox Co., Ltd, Kirin Company, Ltd, Kowa Company, Ltd, Novartis Pharmaceuticals Japan, Santen Pharmaceutical Co. Ltd, and ROHTO Pharmaceutical Co., Ltd. Takeshi Iwata is supported by Japan Agency for Medical Research and Development (AMED) (18ek0109282h0002). Kazushige Tsunoda is supported by AMED, the Ministry of Health, Labor and Welfare, Japan (18ek0109282h0002), Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Japan (H26-26462674), grants from National Hospital Organization Network Research Fund, Japan (H30-NHO-Sensory Organs-03) and Novartis Research Grant (2018). Funding Information: Fight for Sight UK, Early career investigator award; FOUNDATION FIGHTING BLINDNESS ALAN LATIES CAREER DEVELOPMENT PROGRAM, Grant/Award Number: CF‐CL‐0416‐0696‐UCL; Fuji Xerox Co., Ltd; Grant‐in‐Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology, Japan, Grant/Award Number: 16KK01930002; Grant‐in‐Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology, Japan, Grant/Award Number: 16H06269; Grant‐in‐Aid for Young Scientists of the Ministry of Education, Culture, Sports, Science and Technology, Japan, Grant/Award Number: 18K16943; Great Britain Sasakawa Foundation Butterfield Award; Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare, Grant/Award Number: 201711107A; Japan Agency for Medical Research and Development, Grant/Award Number: 18ek0109282h0002; Japan Society for the Promotion of Science, Grant/Award Numbers: 17H06820, 19K09929, H26‐26462674; Kirin Company; Kowa Company, Ltd; National Hospital Organization Network Research Fund, Grant/Award Number: H30‐NHO‐Sensory Organs‐03; NIHR‐BRC at Great Ormond Street Hospital and UCL Institute of Child Health; NIHR‐BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology; Novartis Pharmaceuticals, Japan; Novartis Research Grant, Grant/Award Number: 2018; ROHTO Pharmaceutical Co.,Ltd.; Santen Pharmaceutical Co. Ltd; Tsubota Laboratory, Inc Funding information Funding Information: All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s). Kaoru Fujinami is a paid consultant of Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co., Ltd, and Acucela Inc., Novartis AG., Janssen Pharmaceutical K.K., Sanofy Genzyme, NightStart. Kaoru Fujinami reports personal fees from Astellas Pharma Inc, personal fees from Kubota Pharmaceutical Holdings Co., Ltd., personal fees from Acucela Inc., personal fees from NightStar, personal fees from SANTEN Company Limited, personal fees from Foundation Fighting Blindness, personal fees from Foundation Fighting Blindness Clinical Research Institute, personal fees from Japanese Ophthalmology Society, personal fees from Japan Retinitis Pigmentosa Society. Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan is supported by grants from Astellas Pharma Inc (NCT03281005), outside the submitted work. Akio Oishi receives grant from Novartis AG and Alcon. Akio Oishi reports personal fees from Bayer, Novartis, Alcon, Santen, and HOYA outside the submitted work. Akitaka Tsujikawa receives research grant by Novartis, Bayer, Santen, Canon, Alcon, Bayer, HOYA, Kowa, Pfizer, AMO, Senju, Wakamoto, Japan Medical Industry Association, Tomey, JFC salesplan, Atsuzawa Prosthesis. Akitaka Tsujikawa reports personal fees from Novartis, Alcon, Bayer, Pfizer, Santen, Senju, Nidek, AMO, Kowa, Chugai, Sanwa chemical, Kyoto Soyaku, HOYA, Otsuka, Daiichi Sankyo, Wakamoto, Johnson and Johnson, and Yansen pharma. Funding Information: Kaoru Fujinami is supported by grants from Grant‐in‐Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16H06269), grants from Grant‐in‐Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16KK01930002), grants from National Hospital Organization Network Research Fund (H30‐NHO‐Sensory Organs‐03), grants from FOUNDATION FIGHTING BLINDNESS ALAN LATIES CAREER DEVELOPMENT PROGRAM (CF‐CL‐0416‐0696‐UCL), grants from Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare (201711107A), and grants from Great Britain Sasakawa Foundation Butterfield Awards. Akio Oishi is supported by grants from, Japan Society for the Promotion of Science, Tokyo, Japan (17H06820 and 19K09929). Yu Fujinami‐Yokokawa is supported by grants from Grant‐in‐Aid for Young Scientists of the Ministry of Education, Culture, Sports, Science and Technology, Japan (18K16943). Gavin Arno is supported by a Fight for Sight (UK) Early career investigator award, NIHR‐BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, NIHR‐BRC at Great Ormond Street Hospital and UCL Institute of Child Health, and Great Britain Sasakawa Foundation Butterfield Award, UK. Nikolas Pontikos is funded by a Moorfields Eye Charity Career Development Award (R190031A), the NIHR‐BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology. Toshihide Kurihara is supported by Tsubota Laboratory, Inc, Fuji Xerox Co., Ltd, Kirin Company, Ltd, Kowa Company, Ltd, Novartis Pharmaceuticals Japan, Santen Pharmaceutical Co. Ltd, and ROHTO Pharmaceutical Co., Ltd. Takeshi Iwata is supported by Japan Agency for Medical Research and Development (AMED) (18ek0109282h0002). Kazushige Tsunoda is supported by AMED, the Ministry of Health, Labor and Welfare, Japan (18ek0109282h0002), Grants‐in‐Aid for Scientific Research, Japan Society for the Promotion of Science, Japan (H26‐26462674), grants from National Hospital Organization Network Research Fund, Japan (H30‐NHO‐Sensory Organs‐03) and Novartis Research Grant (2018). Publisher Copyright: © 2020 The Authors. American Journal of Medical Genetics Part C: Seminars in Medical Genetics published by Wiley Periodicals LLC.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Variants in the PROM1 gene are associated with cone (−rod) dystrophy, macular dystrophy, and other phenotypes. We describe the clinical and genetic characteristics of 10 patients from eight Japanese families with PROM1-associated retinal disorder (PROM1-RD) in a nationwide cohort. A literature review of PROM1-RD in the Japanese population was also performed. The median age at onset/examination of 10 patients was 31.0 (range, 10–45)/44.5 (22–73) years. All 10 patients showed atrophic macular changes. Seven patients (70.0%) had spared fovea to various degrees, approximately half of whom had maintained visual acuity. Generalized cone (−rod) dysfunction was demonstrated in all nine subjects with available electrophysiological data. Three PROM1 variants were identified in this study: one recurrent disease-causing variant (p.Arg373Cys), one novel putative disease-causing variant (p.Cys112Arg), and one novel variant of uncertain significance (VUS; p.Gly53Asp). Characteristic features of macular atrophy with generalized cone-dominated retinal dysfunction were shared among all 10 subjects with PROM1-RD, and the presence of foveal sparing was crucial in maintaining visual acuity. Together with the three previously reported variants [p.R373C, c.1551+1G'A (pathogenic), p.Asn580His (likely benign)] in the literature of Japanese patients, one prevalent missense variant (p.Arg373Cys, 6/9 families, 66.7%) detected in multiple studies was determined in the Japanese population, which was also frequently detected in the European population.
AB - Variants in the PROM1 gene are associated with cone (−rod) dystrophy, macular dystrophy, and other phenotypes. We describe the clinical and genetic characteristics of 10 patients from eight Japanese families with PROM1-associated retinal disorder (PROM1-RD) in a nationwide cohort. A literature review of PROM1-RD in the Japanese population was also performed. The median age at onset/examination of 10 patients was 31.0 (range, 10–45)/44.5 (22–73) years. All 10 patients showed atrophic macular changes. Seven patients (70.0%) had spared fovea to various degrees, approximately half of whom had maintained visual acuity. Generalized cone (−rod) dysfunction was demonstrated in all nine subjects with available electrophysiological data. Three PROM1 variants were identified in this study: one recurrent disease-causing variant (p.Arg373Cys), one novel putative disease-causing variant (p.Cys112Arg), and one novel variant of uncertain significance (VUS; p.Gly53Asp). Characteristic features of macular atrophy with generalized cone-dominated retinal dysfunction were shared among all 10 subjects with PROM1-RD, and the presence of foveal sparing was crucial in maintaining visual acuity. Together with the three previously reported variants [p.R373C, c.1551+1G'A (pathogenic), p.Asn580His (likely benign)] in the literature of Japanese patients, one prevalent missense variant (p.Arg373Cys, 6/9 families, 66.7%) detected in multiple studies was determined in the Japanese population, which was also frequently detected in the European population.
KW - PROM1
KW - autosomal dominant
KW - cone dystrophy
KW - cone rod dystrophy
KW - macular dystrophy
UR - http://www.scopus.com/inward/record.url?scp=85089579826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089579826&partnerID=8YFLogxK
U2 - 10.1002/ajmg.c.31826
DO - 10.1002/ajmg.c.31826
M3 - Article
C2 - 32820593
AN - SCOPUS:85089579826
SN - 1552-4868
VL - 184
SP - 656
EP - 674
JO - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics
JF - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics
IS - 3
ER -